Ashurst Advises Fujian Haixi Pharmaceutical on Successful Hong Kong IPO

"Global law firm Ashurst served as Hong Kong and U.S. counsel for Fujian Haixi Pharmaceutical Co., Ltd. (HXPharma) during its global share offering and listing on The Stock Exchange of Hong Kong. This transaction highlights Ashurst's expertise in life sciences capital markets and its role in assisting Chinese pharmaceutical companies in accessing international markets. HXPharma, which focuses on R&D, production, and sales of innovative drug candidates, has a diverse product portfolio, including generic drugs and potential first-in-class therapies. Lead partner Li Jiang emphasized the firm's commitment to supporting Chinese innovators in global capital markets."